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Plasmodium falciparum transmission-blocking vaccines (TBVs) targeting the Pfs25
antigen have shown promise in mice but the same efficacy has never been achieved in
humans. We have previously published pre-clinical data related to a TBV candidate Pfs25-
IMX313 encoded in viral vectors which was very promising and hence progressed to
human clinical trials. The results from the clinical trial of this vaccine were very modest.
Here we unravel why, contrary to mice, this vaccine has failed to induce robust antibody
(Ab) titres in humans to elicit transmission-blocking activity. We examined Pfs25-specific B
cell and T follicular helper (Tfh) cell responses in mice and humans after vaccination with
Pfs25-IMX313 encoded by replication-deficient chimpanzee adenovirus serotype 63
(ChAd63) and the attenuated orthopoxvirus modified vaccinia virus Ankara (MVA)
delivered in the heterologous prime-boost regimen via intramuscular route. We found
that after vaccination, the Pfs25-IMX313 was immunologically suboptimal in humans
compared to mice in terms of serum Ab production and antigen-specific B, CD4+ and Tfh
cell responses. We identified that the key determinant for the poor anti-Pfs25 Ab formation
in humans was the lack of CD4+ T cell recognition of Pfs25-IMX313 derived peptide
epitopes. This is supported by correlations established between the ratio of proliferated
antigen-specific CD4+/Tfh-like T cells, CXCL13 sera levels, and the corresponding
numbers of circulating Pfs25-specific memory B cells, that consequently reflected on
antigen-specific IgG sera levels. These correlations can inform the design of next-
generation Pfs25-based vaccines for robust and durable blocking of malaria transmission.
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While several stages of the malaria parasite life cycle can be
targeted with vaccination, a promising possibility for malaria
elimination and eradication is the development of transmission-
blocking vaccines (TBVs). TBVs work by inhibiting parasite
development in the mosquito midgut through vaccine-elicited
Abs taken up during the blood meal and, therefore, require a
high level of antigen-specific Abs to be maintained over time (1–
4). Among several TBV candidates, Plasmodium falciparum
protein Pfs25 is the most clinically advanced. Pfs25 is
expressed on the surface of zygotes during their development
into ookinetes, and as this process takes place exclusively within
the mosquito, this antigen is not expressed in the human host (3).
Moreover, Pfs25 is highly conserved and a direct correlation
between anti-Pfs25 IgG titers and transmission-blocking activity
(TRA) has been established in animal models, making it an
attractive antigen for a TBV development (1, 5).
In general, monomeric Pfs25 protein has been shown to be
poorly immunogenic, but protein formulationandmultimerization
methods have been able to increase Ab titres (6–10). Here, we have
applied the IMX313 technology, based on a chimeric version of the
oligomerization domain from chicken complement inhibitor C4-
binding protein (C4 bp), in order to obtain homogenous, self-
assembling oligomers of Pfs25. This C4 bp oligomerization
domain has been shown to spontaneously form soluble
heptameric structures when expressed in E. coli (11) and we have
already demonstrated in mice that Pfs25 fused to IMX313 domain
improved Ab responses over the same amount of monomeric
antigen when expressed in ChAd63 and MVA viral vectors (10).
Although this approach showed great promise in mice (10),
relatively low anti-Pfs25 Ab titers were generated in humans in
our Phase I First-in-Human clinical trial (12). In this study, the
transmission reducing activity of the antibodies generated was
weak, but both test vaccines were well tolerated and demonstrated
a favourable safety profile in malaria-naive adults.
Achieving high levels of Abs able to block parasite
development within mosquito likely depends on the
establishment and maintenance of antigen-specific B cells that
upon antigen encounter proliferate and/or terminally
differentiate into plasma cells or memory B cells, which seed
the bone marrow and provide a lasting source of serum Abs.
Critical to efficient stimulation and robust proliferation of
antigen-specific B cells after vaccination and consequent
affinity maturation of produced antigen-specific Abs is the
initiation of germinal centre (GC) activity. Central to the GC
reaction and somatic hyper-mutation (SHM) is the interaction of
GC B cells with GC T follicular helper (Tfh) cells (13, 14). GC
Tfh cells are both required and limiting for the GC reaction (15,
16). GC Tfh cells control the number of GC B cell divisions and
therefore, the amount of SHM by individual GC B cell clones
(17), impacting both quantity and quality of Ab response. GC
Tfh cells express the chemokine receptor CXCR5, which guides
their migration into B cell follicles in response to the CXCL13
ligand, as well as inducible costimulator (ICOS), which potently
promotes class-switching and B cell differentiation into plasma
cells and memory B cells (18–20). A subset of circulatingFrontiers in Immunology | www.frontiersin.org 2CD4+CXCR5+ T cells which share both phenotypic and
functional properties with GC Tfh cells has been identified in
both humans and mice; ongoing GC reactions in peripheral
lymph nodes result in the peripheral blood emergence of
activated CD4+CXCR5+ Tfh cells, characterized by high
expression of ICOS and programmed cell death protein 1
(PD1) in peripheral blood (20, 21).
In order to better understand the differences in humoral
responses, we attempted to gain deeper mechanistic insights
into the development of antigen-specific immune responses in
both mice and humans after vaccination with ChAd63 and
MVA, encoding Pfs25-IMX313. An N-terminal secretion signal
peptide was fused to Pfs25-IMX313 to ensure secretion;
vaccination was delivered intramuscularly, in a heterologous
prime (ChAd63) – boost (MVA) regimen, with an 8-week
interval. We focused on the development of antigen-specific B
cell and Tfh cell responses and correlations of each with humoral
immunogenicity. After exploring both B cell-intrinsic
(specificity, frequency, phenotype, proliferative capacity), and
extrinsic factors (CD4+ T cell help, Tfh cell availability and
specificity) in mice and humans, we found that both correlate
with vaccine-induced Ab titres and contribute to the superiority
of anti-Pfs25 Ab responses in mice over humans.RESULTS
Murine Vaccine-Induced Abs
Demonstrate Superior Transmission-
Reducing Activity to Human
BALB/c mice were primed (Day 0) with 1 × 108 infectious units
(vp) of ChAd63-Pfs25-IMX313 and boosted 8 weeks later (day
56) with 1 × 107 plaque forming units (pfu) of MVA-Pfs25-
IMX313, while the healthy UK adult volunteers enrolled into the
VAC062 trial (ClinicalTrials.gov Identifier : NCT02532049) were
primed with 5 × 1010 vp ChAd63 Pfs25-IMX313 followed by
either 1x108 pfu or 2x108 pfu MVA Pfs25-IMX313 boost
(Groups 2B and 2C, respectively) (12). Sera were collected
from both mice and human volunteers on days 72 (2 weeks
post-boost) and magnitude of the anti-Pfs25 serum IgG Ab
response was assessed by ELISA against Pfs25 recombinant
protein. Responses are reported in mg/ml following conversion
of ELISA arbitrary units (AU) by calibration-free concentration
analysis (CFCA), as direct comparison between murine and
human anti-Pfs25 Ab responses detected by ELISA could not
be performed, due to different sensitivities of the secondary Abs
used. Vaccination using the same ChAd63/MVA Pfs25-IMX313
regimen produced significantly higher serum anti-Pfs25 IgG
responses in mice compared to humans (Figure 1A). To test
the possibility that this difference is due to the discrepancy in
vaccine dose/body weight ratio between mice and humans, we
i.m. immunized mice with full dose (1 × 108 vp of ChAd63-
Pfs25-IMX313 and 1 × 107 pfu of MVA-Pfs25-IMX313), half-
dose (5 × 107 vp of ChAd63-Pfs25-IMX313 and 5 × 106 pfu of
MVA-Pfs25-IMX313) or tenth-dose (1 × 107 vp of ChAd63-
Pfs25-IMX313 and 1 × 106 pfu of MVA-Pfs25-IMX313) of theSeptember 2021 | Volume 12 | Article 732667
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substantially inferior to half-dose and tenth-dose as comparied
to the full dose of the equivalent viral-vectored vaccine
(Supplementary Figures 1A, B).
However, when the equal concentrations of murine and human
Pfs25-specific IgG generated in response to viral vector vaccination
was tested for functional activity in standard membrane feeding
assay (SMFA) (22), murine antigen-specific Abs showed
significantly higher transmission reducing activity (TRA)
compared to human (Figure 1B, Supplementary Table 1). In this
assay, total IgG was first purified from murine and human sera via
Protein G affinity chromatography, followed by affinity purification
of Pfs25-specific IgG using chromatography columns loaded with
Pfs25 antigen. Equal concentrations of murine and human Pfs25-
specific IgGwere then tested in the SMFAandTRAwas determined
as the reduction in the number of oocysts compared to a negative
control lacking protective Ab. When tested at a concentration of
100mg/ml, human anti-Pfs25 Abs did not demonstrate significant
TRA, while, in the same assay, the equivalent concentration of
antigen-specific Abs obtained from mice immunized with the
identical vaccine displayed more than 99% TRA. Moreover,
murine Pfs25-specific IgG showed statistically significant TRA
when tested at the concentration as low as 10 mg/ml (Figure 1B),
confirming that ChAd63/MVAPfs25-IMX313 vaccination induces
qualitatively superior Ab responses in mice compared to humans.
We also confirmed that the functional activity of murine anti-
Pfs25 Abs tested in the SMFA was not influenced by the vaccine
dose given. Purified total murine IgGs obtained from mice
immunized with either full, half or tenth-dose of the same viral
vectored vaccine all displayed more than 99% TRA when tested
at concentrations of 350mg/ml and 125mg/ml in the SMFA
(Supplementary Figure 1C).Frontiers in Immunology | www.frontiersin.org 3Differences in the Effector Functions of
Induced Murine and Human Ab
Subclasses, Ab Avidity and Cross-
Reactivity Do Not Explain Qualitative
Superiority of Murine Pfs25-Specific Abs
To explore the reasons behind functional superiority of murine
vaccine-induced Ab responses over Abs generated in humans, we
investigated the IgG subclasses and avidity of Abs induced after
viral-vector vaccinations in mice and humans. Out of all IgG
subclasses tested, ChAd63/MVA Pfs25-IMX313 vaccination in
mice induced mainly IgG1 and IgG2a responses as measured by
ELISA at d84 (Figure 2A), while in humans the vaccine-induced
serum Ab response against Pfs25, also assessed at d84, was
composed of IgG1,IgG3 and IgM with little to no IgG2 or IgG4
(Figure 2B). Typically, human IgG1 and IgG3 are the most potent
triggers of effector mechanisms, opposite to murine IgG1, which
functionally resembles human IgG4 and does not interact with
complement factors (23).Murine-induced antibodies against Pfs25
have been demonstrated to achieve transmission blocking in the
SMFA in a complement-independent manner (8), but as IgG1 was
the dominant subclass induced in human volunteers afterChAd63/
MVA Pfs25-IMX313 vaccination, we still examined the possibility
that complement could play an important role in improving the
TRAofhumananti-Pfs25 IgG in theSMFA.Wefound that addition
of complement did not impact the TRA in the SMFA when it was
added to three individual human samples with the highest anti-
Pfs25 IgG1 titres (Supplementary Figure 2).
The avidity of the anti-Pfs25 IgG, as measured by a sodium
thiocyanate (NaSCN) displacement ELISA, was comparable at
d84 for both murine and human sera samples (Figure 2C).
Pfs28, another transmission-blocking target antigen, and Pfs25
are genetically linked and structurally similar (24). Moreover, theseA B
FIGURE 1 | Murine vaccine-induced antibodies demonstrate superior transmission-reducing activity to human. (A) Anti-Pfs25 serum total IgG responses for murine
and human samples, as assessed on d72 post ChAd63/MVA Pfs25-IMX313 vaccination. Statistical analysis using 2-tailed Mann-Whitney test ***p < 0.001.
(B) Transmission-reducing efficacy of human and murine anti-Pfs25 IgG induced by the ChAd63/MVA Pfs25-IMX313. Total Pfs25-specific IgG was purified from
either pooled murine or individual human serum obtained on d72 post vaccination. The purified Pfs25-specific human and murine IgG samples were mixed with
P. falciparum NF54 cultured gametocytes, at 100µg/ml and fed to (A) stephensi mosquitoes (n = 20 per test group). Murine samples were also tested at a lower
concentration of 10µg/ml. IgG from naive mice was used as a negative control (“normal mouse Ab”); the transmission blocking anti-Pfs25 mAb 4b7 was used as a
positive control. Midguts were dissected 8 days post-feeding. Transmission reducing activity (%TRA) for human and murine test IgG samples was calculated relative
to the negative control IgG tested in the same assay and is indicated in red above each corresponding sample. Vertical dashed line separates human from murine
samples. Data are from one out of three independent experiments giving similar results.September 2021 | Volume 12 | Article 732667
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redundant functions during ookinete/oocyst development in
Plasmodium berghei parasites (25). We therefore tested the
hypothesis that viral vector vaccination in mice, but not in
humans, generated anti-Pfs25 Abs that were cross-reactive to
Pfs28, contributing to the enhanced TRA in the SMFA of murine
over human anti-Pfs25 IgG. Anti-Pfs25 Abs cross-reactive to Pfs28
were detected in neither murine nor human serum samples
(Figure 2D). Overall, we concluded that qualitatively more
efficient Ab response induced in mice compared to humans after
ChAd63/MVA Pfs25-IMX313 vaccination could not be attributed
to differences between murine and human antigen-specific Ab
avidity, antigen cross-reactivity or differences in the effector
functions of induced Ab subclasses.
Superior Pfs25-specific B Cell Responses
Are Induced in Mice Compared to
Human Volunteers
For the direct assessment of Pfs25-specific immunity at the B cell
level, we examined the frequency and specificity of B cells by flow
cytometry using Pfs25 probes, within PBMC isolated from mouse
and human blood on d84 post ChAd63/MVA Pfs25-IMX313
vaccination (Figure 3A, gating- Supplementary Figures 3A, B).Frontiers in Immunology | www.frontiersin.org 4We detected a sizable population of B cells that were Pfs25-specific
among murine PBMCs (Figure 3B), with the majority comprising
Ab-secreting cells, based on their B220+,GL7-, CD138+, IgDlow
phenotype (Figure 3C). This population was also detectable
within the spleens of immunized mice on d84 (Supplementary
Figure 3C). Moreover, Pfs25 probes allowed us to confirm
expansion of antigen-specific total and GC B cell responses
(B220+, Fas+, GL7+) in murine popliteal (immunization-site
draining) lymph nodes (LNs), as the proportion of antigen-
specific B cells significantly increased at d14 compared to d7
(Supplementary Figure 3D).
Antigen-specific B cells were also identified in human PBMC
samples (Figure 3D, gating- Supplementary Figure 3B), with
considerably higher numbers of vaccine-induced antigen-specific
IgM+ B cells compared to their IgG+ counterparts (Supplementary
Figure 3E). Expectedly, the presence of Pfs25-specific B cells was
observed neither in mouse nor in human d0 samples (Figures 3B,
D). Among circulating PBMCs, we enumerated significantly larger
population of the Pfs25-specific B cells in murine compared to
human samples (Figure 3E). Furthermore, this population of Pfs25-
specific B cells detected within the blood of immunizedmice by flow
cytometry correlated with serum levels of IgG Abs specific for Pfs25
measured on d72 post vaccination (r =0.8313; p = 0.0403)A B
D
C
FIGURE 2 | Assessment of murine and human antibodies’ effector functions, avidity and cross-reactivity. (A) Isotype profiles of murine Pfs25-specific antibody
responses on d84 were assessed by ELISA. Responses are shown for IgG1, IgG2a and IgG2b. (B) Isotype profiles of human serum antibody responses were
assessed by ELISA. Responses are shown for immunization groups 2B and 2C, assessed at d84 for IgG1, IgG2, IgG3, IgG4 and IgM. (C) Avidities of murine and
human serum IgG responses at day 84 were assessed by NaSCN-displacement Pfs25 ELISA and are reported as the molar (M) concentration of NaSCN required
to reduce the starting OD in the ELISA by 50% (IC50) Differences in avidity were assessed by Mann-Whitney test. Each symbol represents an individual response
(ns- not significant). (D) Endpoint anti-Pfs28 IgG titers were assessed by ELISA on human serum samples isolated on d0 (n = 16) and d74 (n = 16) or murine samples
(n = 6) obtained on d74 post ChAd63/MVA Pfs25-IMX313 vaccination. Murine serum sample acquired 2 weeks post boost immunization with recombinant Pfs28
protein in Alum, was used as positive control. Error bars show SEM.September 2021 | Volume 12 | Article 732667
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=0.1512; p = 0.6571) (Figure 3G). Taken together, our data show
that Pfs25 is markedly less immunogenic at both B cell and
serological levels in humans compared to mice after ChAd63/
MVA Pfs25-IMX313 vaccination.
Superior Tfh Cell Activation Is Induced in
Mice Compared to Human Subjects After
ChAd63/MVA Pfs25-IMX313 Vaccination
Given that Tfh cells can be a controlling factor for B cell
responses (26, 27), as they contribute to the development of
Ab responses by providing help to memory B cells (21, 28), we
wondered whether the poorer induction of Pfs25-specific B cells
and Abs in humans following viral-vectored Pfs25-IMX313 is
due to limiting Tfh responses. While direct measurement of GC
responses in humans is often not feasible, a small population of
circulating CXCR5+CD4+ T cells that express ICOS and high
levels of PD1 share functional properties of GC Tfh cells and can
be evaluated as proxies for GC Tfh cells (29).
Using flow cytometry, we assessed Tfh-like responses among
cryopreserved PBMCs isolated from healthy individuals recruited
to groups 2B and 2C of VAC062 trial on d0, d28 and d63 post
ChAd63/MVA Pfs25-IMX313 vaccination (Supplementary
Figures 4A, B). On d63, a population of circulating ICOS+PD1+
cells was detected among both memory (CD3+ CD45RA-
CXCR5+CD4 +) and naive/effector (CD3+CD45RA+CXCR5+
CD4+) Tfh-like cellular compartments (Figure 4A, gating-
Supplementary Figure 4A). Although a change in total memoryFrontiers in Immunology | www.frontiersin.org 5CXCR5+CD4+ Tfh-like cell population detected on d28 relative to
d0 did not correlate with the level of anti-Pfs25 IgG (r =0.3373; p =
0.3151) (Figure 4B), an increase in a subpopulation of those cells
co-expressing ICOS and PD1 on d28 was associated with the sera
concentration of antigen-specific IgGmeasured on d72 (r =0.7793;
p = 0.0047) (Figure 4C), as well as with memory B cell responses
measured by ELISPOT (r = 0.7427; p = 0.0088) (Supplementary
Figure 5A). Similarly, the increase of effector ICOS+PD1+ among
CD4+CD45RA+Tfh-like cells at d63, likely generated in a response
toMVA Pfs25-IMX313 boost, correlated with both the quantity of
specificAbsatd72 (r=0.7039;p=0.0156) (Figure4D) andmemory
B cell responses measured by ELISPOT on d72 (r =0.6227; p
=0.0407) (Supplementary Figure 5B). Furthermore, up-
regulation of ICOS and PD1 expression was found to be mainly
restricted to memory CXCR5+CD4+ T cells that did not express
CXCR3 nor CCR6 (Figures 4A, E), indicating a commitment of
vaccination-induced human blood Tfh cells to the Th2
pathway (21).
Extending these analyses to mice, we examined the
frequency of ICOS+PD1+ among circulating Tfh cells
(CD4+CXCR5+CD44+CD62L-) after ChAd63/MVA Pfs25-
IMX313 vaccination (Figure 4F, gating-Supplementary
Figure 6A). ICOS+PD1+ Tfh cells in blood were not detected at
d7 and d14 post priming, but this population significantly increased
between day 28 and d63 (Figure 4G), likely due to the fast recall
response post MVA-Pfs25-IMX313 boost. Contrary to blood, this
population was readily detectable in the popliteal LNs (Figure 4H,





FIGURE 3 | Differences in murine and human Pfs25-specific B cell responses. (A) Experimental design in mice. (B) Representative FACS plots showing frequencies
of Pfs25-specific B cells accessed among PBMCs isolated from naïve or ChAd63/MVA Pfs25-IMX313 vaccinated mice on d84. (C) Flow cytometry contour plots of
B220 versus GL7 (left panel) or CD138 versus IgD (right panel) expression on PBMC suspensions of mice immunized with ChAd63/MVA Pfs25-IMX313 (gray
contours). Pfs25-specific B220+ cells are represented as an overlay (red contours) to signify that the majority of antigen-specific B cells were indeed B220+,GL7-,
CD138+,IgDlow. (D) Representative FACS plots showing frequencies of Pfs25-specific B cells among total IgM- or IgG-expressing memory B cells from PBMCs of
trial vaccinees isolated on d0 and d84 post ChAd63/MVA Pfs25-IMX313 vaccination. (E) Bar graphs summarizing total numbers of Pfs25-specific B cells detected
among individual murine and human PBMCs on d84 post vaccination. Data represent the mean ± SEM. Mann-Whitney test 2-tailed was performed to compare the
two groups: ***p < 0.001. Correlations between serum anti-Pfs25 IgG concentrations and corresponding numbers of circulating antigen-specific B cells assessed for
murine (F) and human (G) samples. P values were calculated using nonparametric Spearman’s test and are shown in the graphs.September 2021 | Volume 12 | Article 732667
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the draining LNs after priming.
Several studies have shown that murine Tfh cells are capable
of expressing Th1- or Th2-signature cytokines, which contribute
to the regulation of B cell Ig isotype switching (21, 27, 30–32).
Commitment of Tfh cells towards Th1-or Th2- signatures in
mice is usually assessed by the expression of linage-specific
transcription factors (33–35). Therefore, we examined the
expression of T-bet and Gata3, the transcription factors crucial
for differentiation of IFN-g- and IL-4-producing Th1 and Th2
cells respectively (Figure 4H-right panel). ICOS+PD1+ Tfh cells
isolated from the murine popliteal LNs on d14 post ChAd63/
MVA Pfs25-IMX313 vaccination presented with the robust T-
bet expression, with minimal-to-null Gata3 expression,
committing them to Th1-like lineage (Figure 4J).Contrary to
ICOS+PD1+ Tfh cells, Gata3 expression was readily detectable
among total CD4+ T cells (Supplementary Figure 6C).
Overall, we showed that ChAd63/MVA Pfs25-IMX313
vaccination induced Tfh responses in both mice and humans;
however, ICOS+PD1+ Tfh cells detected in healthy adultFrontiers in Immunology | www.frontiersin.org 6vaccinees demonstrated mainly Th2-like properties, while
those in mice were of Th1-like cells, potentially explaining the
differences in induced Pfs25-specific IgG subclasses and their
corresponding Fc effector function profiles in mice and humans.
Limited Antigen-Specific Tfh Response Is
Generated in Humans Following Viral
Vectored Pfs25-IMX313 Vaccination
To rule out the possibility that the Tfh cells we detected in both
mice and humans were not generated mainly in a response to
ChAd63 and MVA antigens, we stimulated cells from
immunized Balbc mice and human vaccinees isolated on d63
post vaccination with overlapping 20-mer synthetic peptide sets
encompassing the Pfs25-IMX313 insert (Supplementary
Figure 7). Antigen-experienced human and murine Tfh were
compared for the expression of the activation markers OX40,
CD25, and/or ICOS, which preferentially identify antigen-
specific Tfh cells compared to traditional intracellular cytokine
staining method (36–38) (Supplementary Figures 8A, B,




FIGURE 4 | Differences in murine and human Tfh cell responses. (A) Flow cytometric plots of the frequency of ICOS+PD1+ cells among either CD4+CD3+CXCR5+
CD45RA+ or CD4+CD3+CXCR5+CD45RA- cells in the peripheral blood of healthy UK volunteers at d63 after ChAd63/MVA Pfs25-IMX313 vaccination. Flow
cytometric assessment of the expression of CXCR3 and CCR6 within ICOS+PD1+CD4+CD3+CXCR5+CD45RA- cells is also shown. Correlations are shown between
serum anti-Pfs25 IgG concentrations measured on d72 post vaccination and corresponding changes in numbers of either circulating (B) CD4+CD3+CXCR5+
CD45RA- cells or (C) ICOS+PD1+CD4+CD3+CXCR5+CD45RA- cells on d28 relative to d0, or corresponding changes in numbers of (D) ICOS+PD1+CD4+CD3+
CXCR5+CD45RA+ cells on d63 relative to d0. P values were calculated using nonparametric Spearman’s test and are shown in graphs. (E) Bars summarising
frequencies of CXCR3-CCR6- (Th2-like), CXCR3+CCR6-(Th1-like) and CXCR3-CCR6+ (Th17-like) Tfh cell populations, among ICOS+PD1+CD4+CD3+CXCR5+
CD45RA- cells as analyzed by flow cytometry. ****P < 0.0001, by one-way ANOVA, error bars show SEM. (F) Representative flow cytometric plots of the frequency
of ICOS+PD1+ cells among CD4+CD3+CXCR5+CD44+CD62L- cells in the peripheral blood of vaccinated mice assessed on d0 and d7 post vaccination. (G) Total
numbers of ICOS+PD1+CD4+CD3+CXCR5+CD44+CD62L- cells detected in peripheral blood of vaccinated mice at indicated time points. (H) Flow cytometry analyses
of ICOS+PD1+CD4+CD3+CXCR5+CD44+CD62L- cells isolated from popliteal LNs of either naïve (d0) or vaccinated mice at d7 post ChAd63 Pfs25-IMX313
immunization. Assessment of intracellular Tbet and Gata3 expression on those cells is also shown (right panel). Summarised data are shown in (I) and (J). **P <
0.01, ****P < 0.0001, by Wilcoxon matched-pairs test, error bars show SEM.September 2021 | Volume 12 | Article 732667
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(39–41). Ex vivo assessment of both murine and human Tfh cell
populations showed significantly greater expansion of peptide
pool stimulated compared to unstimulated (media only) Tfh
cells, irrespective of the surface marker combinations used to
define antigen-specific Tfh cells (Figures 5A-C). Moreover,
antigenic re-stimulation induced significantly larger proportion
of murine Tfh cells co-expressing OX40, CD25, and/or ICOS
compared to the corresponding human populations (Figures 5A,
B). This was also evident when we similarly compared
unstimulated (media only treated) human and murine Tfh
cells in the same assay (Figures 5A, B), suggesting a possible
higher proportion of endogenous vaccination-induced Tfh cells
in mice compared to humans. Together, these results indicate
that the induction of fewer human antigen-specific Tfh cells after
ChAd63/MVA Pfs25-IMX313 vaccination may underpin the
poorer immunogenic potential of Pfs25-IMX313 in humans
compared to mice.
Human Vaccine-Specific CD4+ T Cells
Show Less Proliferative Capacity
Compared to Murine Cells
Exploring the potential reasons for the higher murine antigen-
specific Tfh cellular responses over human elicited to the same
vaccine, we assessed the differences in TCR specificities to Pfs25-
IMX313 of human and murine CD4+ T cells, isolated on d63 post
vaccination. Using CFSE proliferation assay, we analysed CFSE
dilution on human or murine CD4+ T cells, 6 days after ex vivo
recall stimulation with the pool of overlapping 20-mer synthetic
peptide sets encompassing the Pfs-25-IMX313 protein (gating-
Supplementary Figures 9A, B). The recall stimulation led to a
proliferative response in both murine and human CD4+T cells
(Figures 6A, B); however, significantly higher proliferative
capacity to Pfs25-IMX313 peptides was detected with murine
compared to human CD4+ T cells (p < 0.001) (Figure 6C).
Among total human CD4+ T cells, we also assessed the
proliferation of CXCR5-expressing Tfh-like cells (Figure 6D).
Importantly, the rate of proliferated Tfh-like cells isolated from
vaccinated volunteers on d63 was associated with the numbers of
antigen-specific memory B cells, detected among theirFrontiers in Immunology | www.frontiersin.org 7corresponding PBMCs on d84 post vaccination using Pfs25
probes (r = 0.6248; p = 0.039) (Figure 6E). In parallel, we also
assessed the capacity of four separate peptide pools spanning the
entire Pfs25-IMX313 vaccine insert (Supplementary Figure 7) to
induce proliferation of murine and human CD4+ T cells. Lower
frequencies of proliferated polyclonal human CD4+ T cells were
detected in a response to separate stimulation with either of
peptide pools 1-4, compared to frequencies induced by their
cumulative stimulation, or stimulation with the entire Pfs25-
IMX313 protein (Figure 6F, Supplementary Figure 9C).
Surprisingly, in the same experimental settings, murine CD4+ T
cells vastly and almost solely proliferated in response to pool 4, of
which individual peptides cover only the IMX313 portion of the
vaccine insert (Figure 6G, Supplementary Figure 9D).Together,
these results suggest that the ChAd63/MVA Pfs25-IMX313
vaccination induces antigen-specific CD4+ T cell responses that
differ in both strength and specificity between mouse and human.
While, likely due to HLA polymorphism, no dominant epitopes
derived from Pfs25-IMX313 vaccine could be identified for
human CD4+ T cells, the exclusive specificity of murine CD4+
T cells were found to be to epitopes derived from IMX313, but not
from the Pfs25 portion of the immunogen. This significantly
weaker specificity to vaccine derived epitopes observed with
human CD4+ T cells is likely a contributing factor for
insufficient Pfs25-specific B cell responses observed after
ChAd63/MVA Pfs25-IMX313 vaccination.Increased Sera CXCL13 Is Detectable in
Mice, but Not in Healthy Adult Vaccinees
Following ChAd63/MVA Pfs25-IMX313
Vaccination
CXCL13, the chemokine ligand for CXCR5, is central in
structuring GC development and has been described as a
plasma biomarker for GC activity (42). We found that, relative
to pre-vaccination status, the levels of CXCL13 in plasma of mice
immunized with ChAd63/MVA Pfs25-IMX313 significantly
increased when measured one week after the boost (Figure 7A,
Supplementary Figure 10A) and that increase in CXCL13 levels
for individual mice correlated with the corresponding degrees ofA B C
FIGURE 5 | Assessment of antigen specificity of murine and human Tfh cells. Tfh cells were quantified among human PBMCs (n = 14) or murine splenocytes (n = 6)
isolated on d14 after vaccination with ChAd63/MVA Pfs25-IMX313.Antigen-specific, among total Tfh cells were identified either by OX40 upregulation in combination
with ICOS+ (A) or CD25 co-expression (B) or CD154 expression (C) following 18 hours of stimulation with media only or megapool of 20-mer synthetic peptide sets
encompassing the Pfs-25-IMX313 insert (P. megapool). Error bars show SEM. ns - not significant, P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, by
Wilcoxon matched-pairs test.September 2021 | Volume 12 | Article 732667
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assay (r =0.8684; p =0.0248) (Figure 7B).
Compared to pre-vaccination values, overall levels of
CXCL13 detected in plasma of vaccinated volunteers enrolled
to groups 2B and 2C were not significantly higher after priming
with ChAd63-Pfs25-IMX313 or boosting with MVA-Pfs25-
IMX313 (Figures 7C, D, Supplementary Figure 10B). When
assessing individual CXCL13 responses among vaccinees, we
observed that change in CXCL13 levels on d63 relative to d0
mirrored the change in total activated CD4+CXCR5+ICOS+PD1+
Tfh-like cell population detected on d63 after vaccination (r
=0.8681; p =0.0151) (Figure 7E, Supplementary Figure 10B).
Together, this greater induction of CXCL13 and antigen-specific
Tfh cells in mice compared to humans imply increased GC
activity in murine lymphoid tissues, promoting quantitatively
and qualitatively superior antigen-specific Ab responses.DISCUSSION
Various vaccine candidates targeting Pfs25 have been developed
and shown to induce strong transmission-blocking activity in
naive animal models (1, 7, 8, 10, 43–49). However, the identicalFrontiers in Immunology | www.frontiersin.org 8Pfs25-based vaccines that were efficacious in mice (8, 50, 51),
demonstrated limited success in clinical trials (52–54),
highlighting the importance of better understanding the
characteristics of humoral immunity to these Pfs25-based
candidates in mice and humans to assess if it is the quantity or
the quality of antibodies that is the limiting factor in achieving
efficient transmission-blocking. Therefore, we performed a
comparative study that, for the first time, characterized the
immune responses to malaria TBV candidate ChAd63/MVA
Pfs25-IMX313 in healthy adult volunteers and assessed
differences in immunogenicity between mice and humans. We
found that administration of Pfs25-IMX313 encoded by a
replication-deficient ChAd63 and the attenuated MVA, elicited
superior antigen-specific immune responses in mice over
humans, generating higher Pfs25-specific CD4+ T cell and
memory B cell responses and, ultimately, higher and more
robust Ab titers and SMFA activity. The poor humoral
immunogenicity of the Pfs25-IMX313 in humans was
associated with an inability to efficiently elicit CD4+ T cell help
after vaccination. This diminished vaccine-specific CD4+ T cell
help in humans suggests that the Pfs25-IMX313 insert could be
lacking in dominant MHC class II–restricted T cell epitopes as




FIGURE 6 | Proliferative capacity of vaccine-elicited murine and human CD4+ T cells. Cryopreserved and thawed human PBMCs (A) or murine splenocytes (B)
isolated on d63 post vaccine administration were labelled with CFSE, stimulated with either media only or pool of stimulatory 20-mer peptides covering the entire
Pfs25-IMX313 insert (P.megapool) for 6 days and analysed using flow cytometry for dividing (decreased CFSE) CD4+ T cells. As a positive control some cells were
stimulated with staphylococcal enterotoxin B (SEB). Summarized data is shown in (C) Mann-Whitney test 2-tailed was performed to compare the two groups: ***p <
0.001. (D) Flow cytometric assessment of dividing human CXCR5+CD4+ cells in response to stimulation with media only or P. megapool is shown. (E) Correlation
between total numbers of Pfs25-specific memory B cells (CD19+CD20+CD27+) detected on d84 among PBMCs of vaccinated healthy adult individuals and the
percentage of their corresponding CD4+ T cells that divided CFSE in a response to P.megapool stimulation is shown. P value was calculated using nonparametric
Spearman’s test and is shown in the graph. Percentage of human (F) and murine (G) CD4+ T cells that divided CFSE in a response to stimulation with either P.
megapool, recombinant Pfs25 protein or separate stimulation with peptide pools 1-4,where pools 1-3 cover Pfs25 and pool 4 covers IMX313 portion of the vaccine
construct. **P < 0.01, ***P < 0.001, ****P < 0.0001, by one-way ANOVA.September 2021 | Volume 12 | Article 732667
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likely be attributed to heterozygosity of the human HLA class II
type, as the outcome of many infectious diseases and
vaccinations showed strong associations with particular HLA
alleles (55, 56). Previously, when genetically outbred rhesus
macaques were vaccinated with Pfs25 encapsulated into
synthetic particles, mixed antigen-specific CD4+ T cell
responses, ranging from modest to undetectable were reported
(1). Intriguingly, in a response to viral-vector Pfs25-IMX313
vaccination, BalbC mice did not induce detectable Pfs25-specific
CD4+ T cell responses, but strongly activated CD4+ T cells with
the exclusive specificity to IMX313 domain of the vaccine. We
have also previously demonstrated that Pfs25-IMX313 protein
vaccine formulated in Alhydrogel or ASO1 readily induced a
functional antibody response in outbred CD1 mice, although
CD4+ T cell epitope specificity was not investigated in this study
(47). The lack of T cell responses against Pfs25 was also observed
in C57BL/6 mice, whose T cells were unable to bind Pfs25 via the
I-Ab MHC class II molecule (45).
Although a poor Pfs25-specific Tfh cell response is probably
not the exclusive reason explaining the weak Ab response to viral
vectored Pfs25-IMX313 in outbred populations, the murine data
suggest that the magnitude of the Tfh cell response could be a key
factor in determining the immunogenicity of this vaccine. This
information is important to consider while designing future
Pfs25 based immunogens.
We do not exclude the possibility that observed differences in
murine and human anti-Pfs25 responses may also be influenced
by the differences in vaccine doses and subsequent limited
availability of epitopes that could be seen by B cells, resulting
in the weaker Ab responses in humans. Indeed, we observed a
substantial reduction in the anti-Pfs25 IgG levels in mice
immunized with half-dose of viral-vectored Pfs25-IMX313Frontiers in Immunology | www.frontiersin.org 9vaccine. Nevertheless, even this lower quantities of antigen-
specific IgG generated in a response to lower vaccine doses
were still sufficient to demonstrate significant TRA in the
SMFA. Moreover, when equal amounts of Pfs25-specific IgG
isolated from murine and human sera were assessed for
functional activity in the SMFA, murine antigen-specific Abs
demonstrated superior function compared to human antibodies,
likely suggesting the requirement for optimal Tfh responses to
promote class switching and affinity maturation after vaccination
consequently improving the quality of antigen-specific Abs.
Selective induction of Th1-like Tfh cells have been recognized
as important for generating protective Ab responses in various
human infection and immunization studies (57–60), while others
recognized the beneficial role of non-Th1-like human Tfh cells in
eliciting antigen-specific neutralizing Ab responses (61, 62). This
polarization of Tfh cells depends on the stimuli induced by
specific infections or immunizations, enabling Tfh cells to
appropriately support B cell production of the Ab isotype
required to clear the infection. In our study, Th1-like Tfh cell
population was dominant after ChAd63/MVA Pfs25-IMX313
vaccination in mice, while the same vaccine induced Th2-biased
Tfh responses in clinical trial vaccinees. This discrepancy could
be reflected by the ability of differing environmental signals and
innate immune cell responses to Pfs25-IMX313 in shaping Tfh
cells differentiation in mouse and human lymphoid tissues.
Indeed, significant differences between mice and humans in
immune system activation and response to the same antigenic
challenge, in both the innate and adaptive arms, have been
identified, all likely impacted by the evolutionary distance
between the species (63). For example, it has been recognized
that in mice, IL-6 and IL-21 support Tfh cell differentiation,
whereas IL-2 suppresses Tfh cells; differently, IL-12, with IL-23
and transforming growth factor-beta (TGF-b) support Tfh cellsA B
D EC
FIGURE 7 | (A) CXCL13 was measured in murine serum following immunization at indicated time points by ELISA. Data represent mean ± SEM. Significance was
calculated using ANOVA, ***P ≤ 0.001. (B) Correlation of change in CXCL13 levels on d63 relative to baseline with percentage of CD4+ T cells able to divide CFSE in
a response to P.megapool stimulation. Correlation analysis performed using nonparametric Spearman’s test with 2-tailed P value, which is shown in the graph.
CXCL13 was measured in serum of ChAd63/MVA Pfs25-IMX313 vaccinated trial individuals enrolled to groups 2B (C) or 2C (D) at indicated time points by ELISA.
Data represent mean ± SEM. Significance was calculated using one-way ANOVA, ns-P > 0.05. (E) Correlation between changes in CXCL13 levels and numbers of
ICOS+PD1+CD4+CD3+CXCR5+CD45RA+ cells both assessed on d63 post vaccination relative to baseline is shown. Correlation analysis performed using
nonparametric Spearman’s test with 2-tailed P value, which is shown in the graph.September 2021 | Volume 12 | Article 732667
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mice and humans after ChAd63/MVA Pfs25-IMX313
vaccination was also mirrored in production of specific Ab
isotypes with differing abilities to bind FcR or fix complement,
suggesting that production of Th1-supported isotypes and the
selective induction of Th1-like Tfh cells may be important for
generating protective anti-Pfs25 transmission-blocking
responses. As such, skewing Tfh cells away from Tfh2-like and
toward Tfh1-like in humans may represent a potential avenue to
enhance transmission reducing activity of Pfs25 Abs.
Using NaSCN displacement assay, we did not observe
significant differences in avidities between murine and human
anti-Pfs25 Abs. However, this assay measures binding strength of
polyclonal Abs, but the determined avidity index does not always
reflect affinity (67), and possible more finely dissected differences
in monoclonal levels of murine and human Ab responses could
not be assessed. Therefore, the alternative techniques, such as
surface plasmon resonance and biolayer interferometry, are
warranted to measure Ab-binding properties and evaluate true
polyclonal vaccine-induced anti-Pfs25 Ab responses in mice
and humans.
Pfs25-specific memory B cells were evident within our murine
and adult human cohorts. Following immunization with viral
vectored Pfs25-IMX313 vaccines, we observed an expansion of
Pfs25-specific immunity at B cell levels, albeit to a lesser
magnitude in human vaccinees compared to vaccinated mice,
broadly consistent with magnitudes of both T helper cell and
serum Ab responses. We found augmented GC activity over time
in lymphoid tissues of animals vaccinated with Pfs25-IMX313
via viral vectors, as assessed by CXCL13, induction of Tfh cells,
and detection of GC B cells by flow cytometry. In the clinical
study, we did not have access to the vaccine draining LNs to
evaluate GC formations and instead, used other measures for
induction of GC activity (42). Contrary to mice, levels of CXC13
did not significantly increase in humans by priming with
ChAd63 Pfs25-IMX313 or boosting with MVA Pfs25-IMX313,
implying overall weak GC activity in human subjects. This was
also supported by the finding that larger portion of antigen-
specific B cells, detected among human PBMCs, expressed IgM
compared to IgG. As during class-switching, occurring as a
consequence of GC activation, B cells switch from surface IgM
expression to IgG, IgA and IgE isotypes (68), our data suggest
likely absence of adequate GC formations in humans after
ChAd63/MVA Pfs25-IMX313 vaccination. While Pfs25-specific
memory B cells are clearly targetable by vaccination in humans,
the longevity of such responses remains unclear and further
studies into strategies to extend the durability of Pfs25-specific
immunity are warranted.
In summary, we found that the immunological dynamics of
humoral immunity targeting the Pfs25-IMX313 domain are
complex and extrapolating data from mice, we identified
several ways immunogenicity to Pfs25 could be increased for
clinical implementation. Our results demonstrate limited
immunogenicity of the Pfs25 domain in humans after
ChAd63/MVA Pfs25-IMX313 vaccination, a finding consistent
with the already reported poor immunogenicity of this proteinFrontiers in Immunology | www.frontiersin.org 10(52–54). We cannot rule out the idea that different Pfs25-
directed vaccine approaches may have differing immunogenic
potential, given the diverse range of immunogen designs,
expression systems, formulations and immunization schedules.
Although it is encouraging that vaccination of humans can
induce transmission-blocking Abs targeting Pfs25 when
delivered via viral vectors (12), it does seem likely, however,
that boosting the immunogenicity of the Pfs25 via novel
adjuvants, carrier proteins and nanoparticle or viral-particle
formulations will be necessary to elicit robust titers of Pfs25-
immunity in humans. In particular, it would be pertinent to
consider formulations that contain CD4+ T cell epitopes and
adjuvants that trigger pathways known to enhance Tfh cell
differentiation, enabling them to guide an appropriate B cell
response and achieve sufficient amount of high-quality Abs able
to facilitate transmission blocking. Indeed, our results
demonstrate that improving the quantity of antibodies to the
Pfs25 antigen should not be only consideration when designing
Pfs25-based TBVs. In fact, the quality of antibodies induced by
vaccination is of key importance for the efficient malaria
transmission blocking. Moreover, this is likely applicable to
other vaccine candidates aiming to confer antibody-mediated
protection against relevant pathogens.MATERIAL AND METHODS
ChAd63 and MVA Pfs25-IMX313 Vaccines
The design, GMP production and preclinical testing of the viral
vector vaccines used in this study have been reported previously
(10). For the Pfs25-IMX313 constructs a 229 bp DNA fragment
encoding the IMX313 domain was cloned at the C-terminus of
Pfs25. The final antigen insert was codon optimized for
mammalian expression and fused in frame to the human tissue
plasminogen activator (tPA) leader sequence.
The Pfs25-IMX313 insert was subcloned into the ChAd63
and MVA destination and shuttle vectors. ChAd63 Pfs25-
IMX313 was manufactured under current Good Manufacturing
Practice (cGMP) conditions by the Clinical Biomanufacturing
Facility (CBF), University of Oxford, UK, and MVA Pfs25-
IMX313 was manufactured under cGMP conditions by IDT
Biologika GmbH, Germany, both as previously described (69, 70).
Proteins
Recombinant Pfs25 protein for ELISA and B cell assays was
produced from a stably transfected Drosophila melanogaster
Schneider 2 (S2) cell line. Pfs25 sequence (GenBank accession
no: AAN35500, from Alanine-22 to Threonine-193) with three
potential N-linked glycosylation sites (112, 165, 187) mutated,
was codon optimized for expression in insect cells (GeneArt®
Life Technologies, Germany). Cell line generation and growth
conditions have been previously described in detail (71, 72).
Clarified supernatant from a 4-day batch culture of S2 cells was
concentrated 15-20 fold and buffer exchanged using a TFF
system fitted with Pellicon 3 Ultracel 3 kDa membrane (Merck
Millipore, UK). Purification was performed on an AKTA Pure 25September 2021 | Volume 12 | Article 732667
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CaptureSelect™ C-tag column (Thermo Fisher Scientific, UK)
and a polishing size exclusion chromatography (SEC) using
Superdex 200 16/600 PG (GE Healthcare, UK) in 20 mM
TrisHCl, 150 mM NaCl, pH 7.4 (TBS). Purified protein was
quantified by Nanodrop (Thermo Fisher Scientific, UK) and
stored at -80°C until further use.
IMX313 protein used for ELISA was kindly provided by
OSIVAX who owns rights to the IMX313 vaccine technology.
Participants
Healthy, malaria-naive males and non-pregnant females aged
18-50 years were invited to participate in the study. Volunteers
were recruited and vaccinated at the CCVTM, University of
Oxford and at the NIHR CRF in Southampton. In total, twenty
six volunteers were enrolled, with twenty four vaccinated as per
protocol and twenty two completing follow-up. This was a Phase
I open-label, dose escalation, first-in-human, non-randomized
trial of the viral vectored vaccines ChAd63 Pfs25-IMX313 and
MVA Pfs25-IMX313 given in a prime-boost regimen with an
eight week interval (12). The study received ethical approval
from the Oxfordshire Research Ethics Committee A in the UK
(REC reference 15/SC/0237). The study was also reviewed and
approved by the UK Medicines and Healthcare products
Regulatory Agency (MHRA, reference 21584/0344/001-0001).
Volunteers signed written consent forms and consent was
verified before each vaccination. The trial was registered on
Clinicaltrials.gov (NCT02532049) and was conducted
according to the principles of the current revision of the
Declaration of Helsinki 2008 and in full conformity with the
ICH guidelines for Good Clinical Practice (GCP).
Animal Vaccination
All animal experiments and procedures were performed
according to the UK Animals (Scientific Procedures) Act
Project Licence (PPL PA7D20B85) and approved by the
Oxford University Local Ethical Review Body. Age-matched
female BALB/c mice, housed in specific-pathogen free
environments, were vaccinated with equal amount of vaccines
into each legs via the intramuscular route (i.m.) using a
heterologous prime-boost viral-vectored regime, when mice
were primed with 1 × 108 i.u. ChAd63 and boosted 8 weeks
later with 1 × 107 pfu MVA. Vaccines were prepared in sterile
endotoxin-free PBS (Sigma-Aldrich, UK).
Peptides Used for Assessment of
Ag-specific CD4+ T Cell Responses
20-mer peptides, overlapping by 10 amino acids, spanning the
Pfs25 and IMX313 inserts (Supplementary Figure 7) were
purchased from NEO Scientific (Cambridge, MA, USA) and
used for assays as described.
Total IgG ELISAs
ELISAs against Pfs25 recombinant protein were performed using
standardized methodology as previously described for murine
(10, 73) and human (69, 74) samples, except that plates wereFrontiers in Immunology | www.frontiersin.org 11blocked with StartingBlock™ T20 (PBS) Blocking Buffer
(ThermoFisher Scientific,UK).
For Pfs28 endpoint ELISA, Nunc-Immuno maxisorp plates
were coated with recombinant Pfs28 protein, produced from the
Drosophila S2 cells. Indicated serum samples were added in
duplicates and diluted 3 fold down the plate, followed by the
same procedure as for the Pfs25 standardized ELISA. Optical
density (OD) was read at 405 nm using an ELx800 absorbance
microplate reader (Biotek, UK). The endpoint titer is defined as
the X-axis intercept of the dilution curve at an absorbance value
( ± three standard deviations) greater than the OD for a negative
control serum sample.
Avidity ELISAs
Ab avidity was assessed using a sodium thiocyanate (NaSCN)-
displacement ELISA. Nunc-Immuno maxisorp plates were
coated with recombinant Pfs25 protein over-night blocked and
then washed with PBS/T as before. All individual serum samples
were diluted so that each sample contained the same level of
Pfs25 AU (in this study 1 AU). Samples were added in duplicate,
following incubation and washing, an ascending concentration
of the NaSCN (0–7M) was added to the wells. The plates were
incubated at RT for 15 min followed by washing and further
development as before. The avidity ELISA readout was the
intercept of the curve (molar concentration of NaSCN/OD)
where OD reached a 50% reduction of the OD in NaSCN-
free samples.
IgG Subclass ELISAs
For the IgG subclass endpoint ELISA, biotinylated anti-mouse
IgG1 or IgG2a (BD bioscience) was used as the secondary Abs.
After incubation and wash, alkaline phosphatase conjugated
ExtrAvidin (Sigma-Aldrich, UK) was added at 1:5000 in PBS
and incubated for 30 min at RT. The development and
measurement of OD and the endpoint titer determination were
done as before (10).
Human Ab isotype ELISAs were also performed using
methodology described in detail elsewhere (70), except that
plates were coated with recombinant Pfs25 produced from the
Drosophila S2 cells at 2 mg/ml.
CXCL13 ELISAs
Mouse and humanCXCL13 serum concentrations were determined
using LEGEND MAX™ Mouse CXCL13 (BLC) ELISA kit
(BioLegend) and human CXCL13 (BLC) ELISA Kit (Life
Technologies Ltd), respectively, as per manufacturers’ instructions.
Calibration-Free Concentration
Analysis (CFCA)
CFCA was performed as previously described (12, 70, 75), using
a Biacore X100 instrument, a Biotin CAP chip, and X100
control and evaluation software (GE Lifesciences, UK).
Briefly, CFCA was performed using serum samples isolated
either from vaccinated mice or human subjects in Groups 2B
and 2C with a range of Pfs25-specific IgG Ab responses as
assessed by ELISA. Each volunteer’s serum was diluted 1:20,
while individual murine serum samples were diluted 1:500 inSeptember 2021 | Volume 12 | Article 732667
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were obtained by capturing a minimum of 3000 response units
(RU) of Pfs25 antigen on the active flow cell. The CFCA-
measured Pfs25-specific Ab concentrations for each individual
volunteer were analysed by linear regression with the
corresponding total IgG ELISA AU data, with the slope of the
line used to derive an AU-to-µg/mL conversion. The same
principle was applied to determine Pfs25-specific Ab
concentrations in murine serum samples.
Flow Cytometric Detection of Pfs25-
Specific B Cells
Pfs25-specific B cells were identified within cryopreserved
human PBMCs by costaining with Pfs25 probes. Probes were
prepared freshly for each experiment by incubation of
monobiotinylated Pfs25 with streptavidin-PE or streptavidin-
APC at an approximately 4:1 molar ratio to facilitate tetramer
generation (76, 77). The monoclonal Abs used for surface staining
included the following: CD19-PE-Cy7 (HIB19), CD20-BV421
(2H7), IgM-BV510 (MHM-88), CD27-Percp-Cy5.5 (O323) and
IgG-FITC (HP6017), all from BioLegend). For murine splenocyte
and LN samples, tissues were mechanically homogenized into
single-cell suspensions in R10 media (RPMI 1640, 10% FCS, 1×
penicillin-streptomycin-glutamine; Life Technologies, Thermo
Fisher Scientific) and red blood cells lysed with ACK buffer.
Murine cells (PBMCs, splenocytes and LN cells) were surface
stained with the same Pfs25 probes and the following surface Abs:
B220-BV421 (RA3-6B2); IgD-Alexa Flour700 (11-26c.2a); GL7-
Percp-Cy5.5 (GL7); CD138-APC-Cy7 (281-2) and Fas-FITC
(SA367H8), all from Biolegend. Cells were washed twice and
acquired on a BD LSRII and data were analysed in FlowJo
(version 10, Treestar).Flow Cytometric Detection of Activated
and Antigen-Specific Tfh Cells
For ex vivo activated Tfh cell quantification, freshly isolated
murine PBMC or spleen suspensions were stained with the
following Abs: CD3-Alexa Fluor 700 (17A2); CD4+-APC-Cy7
(GK1.5); CXCR5-FITC (L138D7); CD4+4-BV510 (IM7); CD62L-
Percp-Cy5.5 (MEL-14); ICOS-PE (C398.4A); PD1-BV421
(29F.1A12); Tbet-PE-Cy7 (4B10); Gata3-APC (16E10A23), all
from BioLegend, while corresponding human PBMC samples
were stained with CD4+-APC-Cy7 (A161A1); CD3-Alexa Fluor
700 (HIT3a); CD4+5RA-Percp-Cy5.5 (HI100); CXCR5-FITC
(J252D4); ICOS-PE (C398.4A); PD1-Pacific Blue (EH12.2H7);
CCR6-APC (G034E3) and CXCR3-PE-Cy7 (G025H7), all
from Biolegend.
To identify antigen-specific Tfh cells, human or murine cell
samples were cultured in R10 media for 18 hours at 37°C. The
samples were stimulated with a peptide pool (1 mg/peptide/ml)
comprising the Pfs25 (17 peptides) and IMX313 domain (5
peptides) or with a Media/DMSO control. Peptide pools were
generated from a Pfs25-IMX313 peptide array (20-mers
overlapping by 10 amino acids). At the time of stimulation, an
anti-mouse or anti-human–CD154-PE (MR1 and 2431;
respectively, both from BioLegend) were added to all cultureFrontiers in Immunology | www.frontiersin.org 12conditions. After stimulation, cells were washed twice in PBS and
human cells stained with CD3-Alexa Fluor 700 (HIT3a); CD4+-
BV421 (GK1.5); CXCR5-FITC (J252D4); OX40-APC (ACT35);
ICOS-APC-Cy7 (C398.4A); CD25-PE-Cy7 (BC96); and mouse
samples with CD3-Alexa Fluor 700 (17A2); CD4+-BV421 (GK1.5);
CXCR5-Percp.Cy5.5 (L138D7); OX40-APC (OX86); ICOS-APC-
Cy7 (C398.4A); CD25-PE-Cy7 (3C7), all from BioLegend before
being washed and acquired on a BD LSR II using BD FACSDiva.
CSFE Proliferation Assay
Cryopreserved human PBMCs or isolated mouse splenocytes
were resuspended in pre-warmed PBS with 0.1% BSA at a final
concentration of 106 cells/ml and labelled with 750 nM CFSE (5
(6)-Carboxyfluorescein diacetate N-succinimidyl ester;
Molecular Probes™) for 10 min at 37°C, 5% CO2. The staining
was quenched by adding 5 volumes of ice-cold R10 followed by a
5-min incubation on ice. The cells were pelleted, washed and
plated in 96-well round-bottom plates at a concentration of
1x106 cells/well. The CFSE-labelled cells were then stimulated
with 1 mg/peptide/ml of indicated peptide pools, or with 5 mg/ml
whole Pfs25 protein, or 1mg/ml staphylococcal enterotoxinB (SEB)
(positive control) andR10 (negative control) for 6days, stainedwith
a dead cell marker (LIVE/DEAD Fixable Aqua stain; Invitrogen)
and anti-CD4+-APC (BioLegend), anti-CD3-Alexa-Fluor 700
(BioLegend) and anti-CD8-Alexa Flour 780 (Biolegend) mAbs
and acquired on a BD LSR II flow cytometer. Data analysis was
performed using FlowJo software (Tree Star Inc.)
Antigen-Specific Ab Affinity Purification
Pfs25-specific human and mouse IgG samples were generated in
two stages. Serum from immunized mice or healthy adult
volunteers was diluted 2:1 in binding buffer and purification was
performed on anAKTAPure 25 system (GEHealthcare,UK) using
HiTrap™ Protein G HP column (GE Healthcare, UK). Pfs25-
specific IgG was then purified from the total IgG on an AKTA
Pure 25 system (GE Healthcare, UK) using Pfs25-conjugated
HiTrap NHS-Activated HP affinity columns (GE Healthcare,
UK). These were generated using Pfs25 protein and according to
the manufacturer’s instructions. After purification, three rounds of
buffer exchange intoPBSusing anAmicon10KMWCOcentrifugal
filtration device were performed.
SMFA
The ability of vaccine-induced Abs to block the development of P.
falciparum strainNF54was evaluatedusing the SMFAaspreviously
described (5). The percentage of mature Stage V gametocytes was
adjusted to 0.15% ± 0.05% and the male-female ratio is stable
(almost always 1 male: 2–3 female). The positive control mouse
monoclonal Ab 4B7 was used at a concentration of 0.094 mg/mL.
Gametocyte cultures mixed with samples were then fed to 4–6 day
old starved female Anopheles stephensi via a parafilm®membrane.
The mosquitoes were maintained at 26°C and 80% relative
humidity. After 8 days, midguts from twenty mosquitoes per
group were dissected, oocysts counted and the number of infected
mosquitoes recorded. Percent reduction in infection intensity was
calculated relative to the respective control IgG tested in the
same assay.September 2021 | Volume 12 | Article 732667
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Data were analyzed using GraphPad Prism version 6.07 for
Windows (GraphPad Software Inc., California, USA) and R
(version 3.5.1). All tests used to determine significance are
described in the figure legends. A value of P < 0.05 was
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